Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of JLP-1310 vs Metformin and Rosuvastatin in Healthy Volunteers
NCT03690778Phase 1Completed
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Oct 2018
- Primary completion
- Feb 2019
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of JLP-1310 in type 2 diabetes mellitus (T2DM) and hyperlipidemia (2 arms), sponsored by Jeil Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Curve to the last measurable concentration at 48 hours and Maximum Plasma Concentration at 48 hours. Started Oct 2018; status: completed.
02
Drugs
JLP-1310
03
Conditions
type 2 diabetes mellitus (T2DM)hyperlipidemia
Beyond the preview
Go deeper on NCT03690778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03690778.